Stephen Bloch Sells 318,893 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 318,893 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the completion of the transaction, the director owned 1,870,042 shares in the company, valued at $93,932,209.66. This represents a 14.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Liquidia Trading Up 1.7%

Shares of NASDAQ:LQDA traded up $0.99 during midday trading on Wednesday, hitting $57.59. The company had a trading volume of 2,267,546 shares, compared to its average volume of 1,714,195. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $57.80. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of 411.39 and a beta of 0.41. The firm has a fifty day simple moving average of $38.17 and a 200 day simple moving average of $35.29.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 81.61% and a net margin of 7.74%.The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, analysts predict that Liquidia Corporation will post 2.14 EPS for the current year.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the 4th quarter valued at about $25,000. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter valued at about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia in the 3rd quarter valued at about $34,000. Finally, Covestor Ltd raised its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LQDA. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Wells Fargo & Company lifted their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Finally, BTIG Research lifted their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Monday. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $49.33.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s Q1 results topped expectations on both earnings and revenue, with management highlighting record growth and continued profitability, reinforcing confidence in the company’s commercial rollout. Liquidia Corp (LQDA) Q1 2026 Earnings Call Highlights: Record Growth and Strategic Expansion
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and targeted at least $1 billion in net revenue by 2027, signaling strong launch momentum and a sizable growth runway. Liquidia targets at least $1B net revenue in 2027 as YUTREPIA Q1 net product sales rise 44% sequentially
• Positive Sentiment: Several analysts turned more constructive after earnings, including Needham raising its target to $70, BTIG lifting its target to $59, and Wells Fargo setting a $62 target, all of which should support investor sentiment. Liquidia (NASDAQ:LQDA) Price Target Raised to $70.00 at Needham & Company LLC
• Positive Sentiment: LQDA was added to Zacks Rank #1 Strong Buy momentum lists, which can draw additional short-term trading interest from momentum-focused investors. New Strong Buy Stocks for May 13th
• Neutral Sentiment: Liquidia presented at the Bank of America Global Healthcare Conference, which keeps the company in front of investors but did not include a clearly new operational catalyst in the headline. Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: CEO Roger Jeffs sold shares under a pre-arranged 10b5-1 plan; the sale is not necessarily a negative signal, but insider selling can still attract attention. SEC filing
• Negative Sentiment: One recent bearish note argued that YUTREPIA’s launch upside may be nearing a ceiling, suggesting future share gains could become harder to achieve. Liquidia: Yutrepia’s Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).